Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | SVP OPS & PROD DEV | June 07, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date June 07, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,616 |
Reported balance
After 2024-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-07 · Exercise / conversion · Acquired 7,250 · Balance 123,616 F1: The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares. |
| Common StockSEC Table I · non-derivative | Direct | 128,916 |
Reported balance
After 2024-06-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-06-07 · Exercise / conversion · Acquired 5,300 · Balance 128,916 |
| Common StockSEC Table I · non-derivative | Direct | 117,829 |
Reported balance
After 2024-06-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-06-07 · Tax withholding · Disposed 11,087 · Balance 117,829 F2: The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.51 · Expires 2027-03-30 | Direct | 0 |
Reported balance
After 2024-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-07 · Exercise / conversion · Disposed 7,250 · Balance 0 F3: 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.06 · Expires 2028-04-05 | Direct | 0 |
Reported balance
After 2024-06-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-07 · Exercise / conversion · Disposed 5,300 · Balance 0 F4: 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares.
F2: The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price.
F3: 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.
F4: 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2018 Filed Apr 10, 2018 21:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 144 | $57.06 | $8,216.64 |
DisclosureSEC source: 0001144204-18-019988 · tv490745_4.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,448 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 21:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 5,300 | $0.00 Strike: $57.06 | $0.00 |
DisclosureSEC source: 0001144204-18-019988 · tv490745_4.xml · derivative · entry 3 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2028-04-05 F1 · security: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. F1 · derivative.exercise_date: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 21:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-019988 · tv490745_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,592 F1 · security: The restricted stock and the stock options vests, and are exercisable, in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 21:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 278 | $58.22 | $16,185.16 |
DisclosureSEC source: 0001144204-18-018996 · tv490180_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,192 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. F1 · price: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 3,208 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001144204-18-013389 · tv487936_4.xml · derivative · entry 5 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 3,208 shares Expires 2023-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Options · Derivative | 14,793 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001144204-18-013389 · tv487936_4.xml · derivative · entry 4 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,793 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,177 | $61.92 | $258,639.84 |
DisclosureSEC source: 0001144204-18-013389 · tv487936_4.xml · nonDerivative · entry 3 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,470 F1 · price: This transaction was executed in multiple trades at prices ranging from $62.80 to $63.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 3,208 | $33.00 | $105,864.00 |
DisclosureSEC source: 0001144204-18-013389 · tv487936_4.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 14,793 | $6.36 | $94,083.48 |
DisclosureSEC source: 0001144204-18-013389 · tv487936_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:30 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 278 | $47.01 | $13,068.78 |
DisclosureSEC source: 0001144204-17-029344 · v467760_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,549 F1 · kind: The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:03 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 7,250 | $0.00 Strike: $49.51 | $0.00 |
DisclosureSEC source: 0001144204-17-018955 · v463546_form4.xml · derivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2027-03-30 F1 · security: The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:03 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 3,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-018955 · v463546_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,827 F1 · security: The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.